Bepirovirsen Accepted for Regulatory Review in Japan as a Potential First-In-Class Treatment for Chronic Hepatitis B
February 26, 2026
February 26, 2026
LONDON, England, Feb. 26 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B
- Submission supported by statistically significant and clinically meaningful functional cure rates demonstrated in pivotal phase III B-Well trials
- Nearly 1 million people in Japan live with chronic . . .
* * *
Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B
- Submission supported by statistically significant and clinically meaningful functional cure rates demonstrated in pivotal phase III B-Well trials
- Nearly 1 million people in Japan live with chronic . . .